English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe study reports on the response to “pressure sensor-based autoregulation of blood flow” in ten patients for up to two years after implantation of the Carmat Total Artificial Heart (C‑TAH). “The C‑TAH Auto-Mode with built-in pressure sensors effectively produces appropriate physiological responses reflective of changing patients’ daily needs and thus provides almost physiological heart replacement therapy,” according to the new research. The lead author is Ivan Netuka, MD, of the Institute for Clinical and Experimental Medicine, Prague.
Auto-Mode may increase independence and quality of life in severe heart failure
Heart replacement pumps can restore cardiac output in patients with end-stage, biventricular heart failure (affecting both sides of the heart) whose only other option is heart transplantation. However, to enable patients to go home from the hospital and return to their usual activities, the pump should emulate normal heart function, with minimal need for adjustment.
To meet that goal, the C‑TAH incorporates an Auto-Mode that automatically adapts the pumping action of the right and left ventricles in response to pressure sensors located inside the device, based on parameters set by the physician. The goal is to mimic normal physiological responses to changing needs – particularly physical activity.
Dr. Netuka and colleagues analyzed the Auto-Mode’s performance in the first 10 patients undergoing C‑TAH implantation in early European clinical experience. The patients were all men, average age 60 years. The C‑TAH was used as a bridge to heart transplantation in six patients and as a permanently implanted device in four.
In all patients, the artificial heart was successfully switched from manual control to Auto-Mode in the operating room. Auto-Mode led to “an immediate appropriate cardiac output response” to the targeted settings. Hemodynamic data recorded by the C‑TAH showed expected variations in pumping output of the left and right ventricles, in response to changes in pressures and heart rate. Heart rate averaged 78 to 128 beats per minute; blood pressure was normal as well.
Over almost five years of aggregate follow-up, medical teams made changes in the Auto-Mode settings just 20 times. Most adjustments were performed during the first 30 days after device placement. Only four were done after the patient went home from the hospital: a rate of about 1 change per 11 months.
“The reduced need for device management changes may contribute to greater autonomy for patients outside of the hospital environment and improvement in their quality of life,” Dr. Netuka and coauthors write. They acknowledge that their study is an initial experience in a relatively small number of patients.
“Nevertheless,” they add, “it represents a significant leap towards the next stage more physiological heart replacement therapy. The overall experience of more than four years of device performance represents a positive and promising outcome for the patients while requiring only minimal intervention from the clinicians.” The researchers plan further refinements based on the preliminary results; future studies will provide data on response to exercise and hospital readmission rates. A US clinical trial of the C‑TAH is scheduled to begin soon.
DOI: 10.1097/MAT.0000000000001485
###
About ASAIO Journal
ASAIO Journal, the official publication of the American Society for Artificial Internal Organs, is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Published in eight issues annually, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
